T
Teruaki Fujishita
Researcher at Kyoto University
Publications - 20
Citations - 1179
Teruaki Fujishita is an academic researcher from Kyoto University. The author has contributed to research in topics: Colorectal cancer & Metastasis. The author has an hindex of 12, co-authored 18 publications receiving 834 citations.
Papers
More filters
Book ChapterDOI
Oncogenic Roles of the PI3K/AKT/mTOR Axis
Masahiro Aoki,Teruaki Fujishita +1 more
TL;DR: Possible mechanisms by which the PI3K/AKT/mTOR axis contributes to oncogenic transformation include stimulation of proliferation, survival, metabolic reprogramming, and invasion/metastasis, as well as suppression of autophagy and senescence.
Journal ArticleDOI
Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC
Kiyotoshi Satoh,Shinichi Yachida,Masahiro Sugimoto,Minoru Oshima,Toshitaka Nakagawa,Shintaro Akamoto,Sho Tabata,Kaori Saitoh,Keiko Kato,Saya Sato,Kaori Igarashi,Yumi Aizawa,Rie Kajino-Sakamoto,Yasushi Kojima,Teruaki Fujishita,Ayame Enomoto,Akiyoshi Hirayama,Takamasa Ishikawa,Makoto Mark Taketo,Yoshio Kushida,Reiji Haba,Keiichi Okano,Masaru Tomita,Yasuyuki Suzuki,Shinji Fukuda,Masahiro Aoki,Tomoyoshi Soga +26 more
TL;DR: It is shown that metabolic reprogramming of colorectal cancer is caused chiefly by aberrant MYC expression, and inhibition of MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS blocked cell growth, and thus are potential targets for coloreCTal cancer therapy.
Journal ArticleDOI
Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ716 mice
TL;DR: It is proposed that the mTOR inhibitors may be efficacious for therapy and prevention of colonic adenomas and cancers with Wnt signaling activation.
Journal ArticleDOI
Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model
Takanori Kitamura,Teruaki Fujishita,Pius Loetscher,Laszlo Revesz,Hiroki Hashida,Shinae Kizaka-Kondoh,Masahiro Aoki,Makoto Mark Taketo +7 more
TL;DR: It is suggested that CCR1 antagonists can provide antimetastatic therapies for patients with disseminated colon cancer in the liver because of their role in tumor invasion and metastasis.
Journal ArticleDOI
Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
Yoshiro Itatani,Kenji Kawada,Teruaki Fujishita,Fumihiko Kakizaki,Hideyo Hirai,Takuya Matsumoto,Masayoshi Iwamoto,Susumu Inamoto,Etsuro Hatano,Suguru Hasegawa,Taira Maekawa,Shinji Uemoto,Yoshiharu Sakai,Makoto Mark Taketo +13 more
TL;DR: In human CRC cells, loss of SMAD4 leads to up-regulation of CCL15 expression, a human ortholog of mouse CCL9, which facilitates tumor invasion and metastasis and could prevent metastasis of CRC to liver.